User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.

Primary tabs

download
  • Open access
  • PDF
  • 464.49 K
Buisseret, Laurence Loirat, Delphine Aftimos, Philippe Maurer, Christian Punie, Kevin Taylor, Donatienne [UCL] Duhoux, François [UCL] Piccart-Gebhart, Martine

(eng) Correction to: Nature Communications 10.1038/s41467-023-42744-y, published online 02 November 2023. In the “Discussion” section of the original manuscript, the authors reported information and data related to an unpublished work (Metoikidou C. and colleagues). [...]

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès libre
Publication date 2023
Language Anglais
Journal information "Nature communications" - Vol. 14, no. 1, p. 8223 (2023)
Peer reviewed yes
Publisher Nature Pub. Group ((United Kingdom) London)
e-issn 2041-1723
Publication status Publié
Affiliations UCL - SSS/IREC/MONT - Pôle Mont Godinne
UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie
UCL - (MGD) Service d'oncologie médicale
UCL - (SLuc) Service d'oncologie médicale
Links
Bibliographic reference Buisseret, Laurence ; Loirat, Delphine ; Aftimos, Philippe ; Maurer, Christian ; Punie, Kevin ; et. al. Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.. In: Nature communications, Vol. 14, no. 1, p. 8223 (2023)
Permanent URL http://hdl.handle.net/2078.1/283200